Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3), widely known as PERK, is a type I transmembrane protein located in the endoplasmic reticulum (ER) that serves as a primary sensor for the unfolded protein response (UPR) [1, 2, 10]. Under conditions of ER stress, such as the accumulation of misfolded proteins, PERK undergoes dimerization and autophosphorylation to become active [3, 10]. Once activated, it phosphorylates the alpha subunit of eukaryotic initiation factor 2 (eIF2α), which results in a rapid, global attenuation of protein translation to reduce the workload on the ER [1, 2, 10]. Simultaneously, this signaling pathway selectively promotes the translation of specific mRNAs, including the transcription factors ATF4 and CHOP, which coordinate adaptive or apoptotic responses [2, 10, 14]. EIF2AK3 plays a dual role in disease; its overactivation is linked to neurodegeneration and proteinopathies like Alzheimer's disease, while its activity supports the survival of tumor cells in harsh microenvironments [9, 10, 14, 16]. Consequently, PERK is a significant therapeutic target, with inhibitors being explored for oncology and neuroprotection [4, 9, 10]. However, drug development is complicated by the protein's essential role in pancreatic beta-cell health, as its loss or inhibition can lead to diabetes and pancreatic insufficiency [1, 11, 16].
Kinase inhibition (ATP-competitive), Kinase activation [4, 10]
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic translation initiation factor 2-alpha kinase 3 [1, 3, 10] (EIF2AK3 [1, 3, 10]).